1. Scrip

Favorable Japan Environment Nurtures Daiichi/CTL Cell Therapy Deal

 
• By Ian Haydock

Daiichi Sankyo's recent deal for Japan rights to a cell therapy agent illustrates the ongoing corporate appetite for assets able to benefit from the country's favorable regulatory framework for such products.

Daiichi Sankyo Co. Ltd.'s move to jump-start its pipeline in the regenerative medicine area by acquiring rights in Japan to a novel cell therapy continues a trend for pharma majors in the country to enter a field characterized by a highly supportive domestic regulatory environment.

The Japanese firm has licensed in Cell Therapy Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

 
• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.